Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Diluted Average) (2018 - 2025)

Historic Shares Outstanding (Diluted Average) for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Q1 2025 value amounting to $161.0 million.

  • Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) rose 207.61% to $161.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $161.0 million, marking a year-over-year increase of 207.61%. This contributed to the annual value of $160.7 million for FY2020, which is 296.88% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $161.0 million for Q1 2025, which was up 207.61% from $159.0 million recorded in Q2 2024.
  • Ironwood Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $161.0 million for Q1 2025, and its period low was $155.4 million during Q2 2023.
  • For the 3-year period, Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $158.3 million, with its median value being $158.4 million (2024).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) skyrocketed by 234.73% in 2024, and later surged by 207.61% in 2025.
  • Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $155.4 million in 2023, then grew by 2.35% to $159.0 million in 2024, then rose by 1.23% to $161.0 million in 2025.
  • Its last three reported values are $161.0 million in Q1 2025, $159.0 million for Q2 2024, and $157.7 million during Q1 2024.